Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
SARS-CoV-2 Mpro Inhibitor
CDD-1819 is a potent non-covalent, non-peptide inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting a Ki of 5 nM. This compound effectively inhibits mutant variants including ΔP168, A173V, and ΔP168/A173V Mpro. CDD-1819 serves as a valuable tool in research focused on COVID-19 therapeutic development and the mechanistic study of viral protease function. -
SARS-CoV-2 Mpro Inhibitor
NVP-EGT710 is an orally active, non-peptidomimetic covalent inhibitor of the SARS-CoV-2 main protease (Mpro). This compound demonstrates potent inhibitory activity against Mpro, making it a valuable tool for studying coronavirus infections. Its mechanism of action and specificity provide a promising avenue for research focused on antiviral therapeutics targeting SARS-CoV-2. -
SARS-CoV-2 Inhibitor
AT-9010 is a triphosphate active metabolite of AT-527 that serves as a potent inhibitor of the NiRAN enzyme, which is essential for the replication of SARS-CoV-2. This compound effectively inhibits the replication of the virus, making it a valuable tool for research into therapeutic strategies targeting COVID-19 and related coronaviruses. Its mechanism of action positions AT-9010 as a promising candidate for advancing our understanding of antiviral therapies. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-16 is a covalent inhibitor targeting the SARS-CoV-2 3CL protease, exhibiting an IC50 of 2.124 μM. This compound selectively binds to the active site of the enzyme, forming a covalent bond with the cysteine residue at position 145. It is a valuable reagent for studying the inhibition of viral replication and may be utilized in research focused on developing antiviral therapies for COVID-19. -
SARS-CoV-2 Proteases Inhibitor
Methyl tanshinonate is a natural product derived from Salvia miltiorrhiza, targeting SARS-CoV-2 proteases. It exhibits potent inhibitory activity against the Mpro enzyme, with an IC50 value of 21.1 µM. This compound holds potential for research applications in the study of SARS-CoV-2 as well as diabetes-related investigations. -
SARS-CoV-2 Mpro Inhibitor
CDD-1733 is a potent non-covalent, non-peptide inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an inhibitory constant (Ki) of 12 nM. This compound is effective against various Mpro variants, including ΔP168, A173V, and ΔP168/A173V. CDD-1733 is essential for research focused on antiviral drug development and the mechanistic study of SARS-CoV-2 pathogenesis. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-57, a potent inhibitor of SARS-CoV-2, exhibits an IC50 value of 80 nM, demonstrating significant antiviral activity. This compound has a high affinity for Sigma receptors, with Ki values of 13.6 nM for the Sigma-1 receptor and 14.4 nM for the Sigma-2 receptor. SARS-CoV-2-IN-57 is specifically designed for research applications focused on understanding and inhibiting SARS-CoV-2 viral mechanisms and interactions. -
SARS-CoV-2 Inhibitor
Z795161988 is a specific inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase, demonstrating an IC50 of 2.2 μM. This compound exhibits significant antiviral activity, making it a valuable tool for research focused on SARS-CoV-2 replication and pathogenesis. Its use in biochemical assays can facilitate the understanding of viral methylation processes and aid in the development of effective therapeutic strategies against COVID-19. -
SARS-CoV-2 3CLpro Inhibitor
3CPLro-IN-2 is a potent inhibitor of the SARS-CoV-2 3CLpro enzyme, demonstrating an IC50 of 1.55 μM and a Ki of 6.09 μM. The 3-chymotrypsin-like cysteine protease plays a crucial role in the viral replication process, making it a compelling target for therapeutic intervention in COVID-19 research. This compound has potential applications in the development of antiviral strategies aimed at mitigating SARS-CoV-2 infection. -
SARS-CoV-2 NPro Inhibitor
SARS-CoV-2-IN-17 is a potent inhibitor of the SARS-CoV-2 nucleocapsid protein (NPro). It demonstrates significant antiviral activity, with an EC50 of 2.18 μM. The compound binds to NPro with a low KD value of 7.82 μM, establishing it as a strong ligand for NPro. This reagent is valuable for research applications targeting SARS-CoV-2 and understanding its viral mechanisms. -
SARS-CoV-2 3CL Protease Inhibitors
MAC-5576 is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 of 81 nM. Additionally, it inhibits HAV 3C protease and thrombin with IC50 values of 0.5 μM and 13 μM, respectively. This compound serves as a valuable tool for research into antiviral therapies and protease inhibition mechanisms, particularly in the context of COVID-19. Its profile supports investigations into viral replication and potential therapeutic strategies. -
SARS-CoV Inhibitor
Isomitomycin A is a potent SARS-CoV-2 inhibitor that targets the hACE2 binding site of the viral spike glycoprotein. This compound demonstrates significant antiviral activity, making it a valuable tool for research into COVID-19 mechanisms and potential therapeutic interventions. Its application in studies related to SARS-CoV-2 reinforces its importance in the ongoing exploration of effective treatments for coronavirus infections. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-17 is a selective inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 0.322 μM. This compound targets the viral protease, disrupting the proteolytic processing of viral polyproteins, thereby inhibiting viral replication. It is a valuable tool for research focused on antiviral drug development and the study of SARS-CoV-2 biology. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 3CLpro-IN-28 is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 of 0.018 μM. This compound effectively disrupts viral replication by targeting the enzymatic function essential for the processing of viral polyproteins. It is a valuable tool for research focused on antiviral strategies and the development of therapeutic agents against COVID-19. -
SARS-CoV-2 Inhibitor
ZINC475239213 is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase, exhibiting an IC50 of 20 μM. This compound demonstrates potential antiviral activity by disrupting viral replication mechanisms. It is suitable for research applications focused on COVID-19 and the development of therapeutic strategies against SARS-CoV-2. -
SARS-CoV-2 3Mpro Inhibitor
SARS-CoV-2 Mpro-IN-28 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), with an EC50 value of 24 μM. This compound is essential for studying the replication and pathogenesis of SARS-CoV-2. It plays a significant role in evaluating therapeutic strategies targeting viral protease activity and can facilitate the development of antiviral agents against COVID-19. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-31 is a potent inhibitor of SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 11 nM. This compound also significantly inhibits the enzymatic activity of cysteine proteases cathepsin B and cathepsin L, with IC50 values of 24 nM and 1.8 nM, respectively. Its high specificity and efficacy make SARS-CoV-2 Mpro-IN-31 a valuable tool for research related to coronavirus pathology and enzyme regulation. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-95 is a potent inhibitor of the SARS-CoV-2 papain-like protease (PLpro) with an IC50 value of 0.39 μM. This compound demonstrates significant antiviral activity in mouse models of SARS-CoV-2 infection, making it a valuable tool for research on COVID-19 antiviral strategies and therapeutic development. -
SARS-CoV-2 Inhibitor
RU-0415529 is an orally bioavailable inhibitor targeting SARS-CoV-2 nonstructural protein 14 (NSP14), with an IC50 value of 356 nM. This compound effectively binds to the SAH-stabilized cap binding pocket, disrupting viral RNA methylation and subsequent viral replication. RU-0415529 demonstrates potent anti-infectious activity in mouse models, making it a valuable tool for research on SARS-CoV-2 virology and potential therapeutic applications. -
SARS-CoV-2 Mpro Inhibitor
NZ-804 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 8.9 nM. This compound effectively reduces SARS-CoV-2 replication in HeLa-hACE2 cells, with an EC50 of 14 nM. NZ-804 demonstrates broad-spectrum antiviral activity against various coronaviruses and has been shown to significantly diminish viral replication in mouse and hamster models, making it a valuable tool for research into COVID-19 and related viral infections. -
SARS-CoV-2 Papain-like Protease Inhibitor
Jun13296 is an orally active quinoline compound that functions as a potent inhibitor of the SARS-CoV-2 papain-like protease, with an IC50 of 0.13 µM and a Ki of 8.8 nM. This reagent demonstrates significant inhibitory activity against various SARS-CoV-2 variants, including those resistant to Nirmatrelvir. In in vivo studies, Jun13296 effectively reduces lung viral titers and mitigates lung tissue damage in models of SARS-CoV-2 infection, making it a valuable tool for COVID-19 research and therapeutic development. -
SARS-CoV-2 Inhibitor
MePT-S-N-Pme is an inhibitor of SARS-CoV-2 RNA-dependent RNA polymerase (RdRp). This compound exhibits significant antiviral activity, demonstrating reduced reporter activity with an IC50 of 7 μM in HEK 293 cells. Additionally, MePT-S-N-Pme shows a mild inhibitory effect on nucleotidyltransferase activity. Given its ability to significantly inhibit SARS-CoV-2 replication in vitro, MePT-S-N-Pme is a valuable tool for antiviral research and the development of therapeutic strategies against COVID-19. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-18 is a covalent inhibitor targeting the SARS-CoV-2 3CL protease, with an IC50 of 0.478 μM. This compound exhibits antiviral activity against SARS-CoV-2 in Vero E6 cells, demonstrating an EC50 of 2.499 μM, while maintaining low cytotoxicity (CC50 > 200 μM). It serves as a valuable tool for research on SARS-CoV-2 inhibition and the development of therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 3CLpro-IN-15 is a beta-nitrostyrene compound that serves as an inhibitor of the SARS-CoV-2 3C-like protease (3CLpro). This compound effectively inhibits viral replication and transcription, making it a valuable tool in the search for anti-COVID-19 lead compounds. Its mechanism of action highlights its potential in therapeutic applications against SARS-CoV-2 and related coronaviruses. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-59 is a non-peptide small molecule inhibitor targeting the main protease (Mpro) of SARS-CoV-2. This imidazoline derivative demonstrates significant interaction with critical residues in the Mpro active site, including Met 165, Gln 166, His 41, and Gln 189. SARS-CoV-2-IN-59 is a valuable tool for studying viral pathogenesis and potential therapeutic strategies against COVID-19. -
SARS-CoV-2 nsp13 Inhibitor
SARS-CoV-2 nsp13-IN-6 is a selective inhibitor of the non-structural protein 13 (nsp13) of SARS-CoV-2, demonstrating IC50 values of 27 μM and 33 μM for single-stranded DNA-dependent ATPase activity. This compound serves as a valuable tool for investigating the mechanisms of SARS-CoV-2 replication and offers potential applications in the development of therapeutic strategies against COVID-19. Its inhibition of nsp13 highlights its relevance in antiviral research aimed at disrupting viral replication. -
SARS-CoV-2 NSP14 Inhibitor
TDI-014925 is a potent inhibitor of the SARS-CoV-2 nonstructural protein 14 (NSP14) with an IC50 of 0.2 nM. This compound exhibits significant antiviral activity and demonstrates excellent microsomal stability without CYP inhibition. TDI-014925 is suitable for research applications related to COVID-19 and the biochemical characterization of viral methyltransferase functions. -
SARS-CoV Inhibitor
NK007 is a potent inhibitor of SARS-CoV-2, demonstrating an EC50 value of 30 nM. This compound disrupts viral replication, making it a valuable tool for studying SARS-CoV-2 infection mechanisms and evaluating potential therapeutic strategies against COVID-19. Its efficacy in inhibiting viral activity positions NK007 as a significant reagent for research in virology and infectious disease. -
SARS-CoV-2 Mpro Inhibitor
UAWJ-247 is a potent and reversible inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 value of 0.042 μM and a Ki of 0.035 μM. This compound demonstrates significant antiviral activity, making it a valuable tool for research into therapeutic strategies against COVID-19. Its efficacy in inhibiting virus replication positions UAWJ-247 as a relevant agent for studies focused on SARS-CoV-2 drug development. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-38 is an inhibitor targeting the SARS-CoV-2 virus, demonstrating significant potential in antiviral research. This compound exhibits favorable oral bioavailability in murine models, achieving a bioavailability rate of 39.75%. It is relevant for studies focused on the development of therapeutics aimed at combating COVID-19 and related viral infections. -
SARS-CoV nsp14 Inhibitor
SARS-CoV-IN-4 is a potent inhibitor of the SARS-CoV nsp14 N7-methyltransferase, with an IC50 of 0.6 μM. This compound offers specificity in targeting the N7-methyltransferase activity, making it a valuable tool for studying viral RNA modification processes. SARS-CoV-IN-4 is relevant for research applications related to antiviral drug discovery and the mechanistic understanding of SARS-CoV replication and pathogenesis. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-44 is a potent inhibitor targeting SARS-CoV-2, effectively blocking viral replication with an EC50 of 0.6 μM. The compound demonstrates minimal cytotoxicity in Calu-3 cells, making it suitable for antiviral research. Its profile supports investigations into therapeutic strategies against SARS-CoV-2 infection. -
SARS-CoV-2 Inhibitor
Crepidiaside B is a natural compound derived from Cichorium intybus that functions as an inhibitor of the SARS-CoV-2 spike glycoprotein. This compound exhibits antiviral activity and is utilized in research studies focused on coronavirus disease 2019 (COVID-19) and the mechanisms of viral entry into host cells. Its potential therapeutic implications make it a valuable tool in the ongoing efforts to combat SARS-CoV-2. -
SARS-CoV-2 Inhibitor
CMX990 is an inhibitor of the SARS-CoV-2 3CL protease, demonstrating potent antiviral activity with EC90 values of 9.6 nM in human bronchial epithelial cells and 101 nM in HeLa-ACE2 cells. This reagent exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties, making it suitable for research in virology and drug development targeting coronavirus infections. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-12 is an inhibitor of the SARS-CoV-2 main protease (Mpro), a critical enzyme in the viral life cycle. This compound demonstrates potent antiviral activity, making it a valuable tool for studying viral replication mechanisms and developing therapeutic strategies against COVID-19. Its specificity for Mpro allows for focused research on the inhibition of SARS-CoV-2 and the evaluation of potential antiviral agents. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-20 is a targeted inhibitor of SARS-CoV-2 with an effective concentration (EC50) of 6.5 μM. This compound demonstrates significant antiviral activity, making it a valuable tool for research applications focused on infectious diseases, particularly COVID-19. Its inhibitory properties enable studies on viral replication and therapeutic interventions. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2-IN-12 is a potent inhibitor of the SARS-CoV-2 3C-like protease (3CLpro), demonstrating a Ki value of 32.1 pM. This compound effectively prevents viral replication, making it a valuable tool for research applications focused on COVID-19. Its high potency and specificity aid in investigations aimed at understanding and developing therapeutic strategies against SARS-CoV-2. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 Mpro-IN-9 is a nonpeptidic, noncovalent inhibitor targeting the main protease (Mpro) of SARS-CoV-2, exhibiting an IC50 of 0.085 μM. This compound demonstrates effective inhibition of viral replication in SARS-CoV-2-infected Vero E6 cells, with an EC50 of 1.10 μM, while showing low cytotoxicity (CC50 > 50 μM). SARS-CoV-2 Mpro-IN-9 is significant for research applications focused on antiviral strategies against COVID-19 and the development of therapeutic agents. -
SARS-CoV-2 NSP14 MTase Inhibitor
NSC111552 is a selective inhibitor of the SARS-CoV-2 NSP14 methyltransferase (MTase), demonstrating significant potency. It effectively disrupts FL-NAH binding to the NSP14 MTase with an IC50 value of 5.1 μM. This compound is valuable for research into SARS-CoV-2 replication processes and the development of antiviral therapies targeting the viral MTase activity. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-32 is a highly potent inhibitor of the SARS-CoV-2 3CLpro enzyme, characterized by an IC50 value of 0.109 μM. In addition to its inhibitory effects on SARS-CoV-2, this compound demonstrates antiviral activity against the coronavirus HCoV-OC43, with an EC50 of 1.99 μM. It is a valuable tool for researchers studying viral replication and therapeutic strategies against coronavirus infections. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-84 is a selective inhibitor of the SARS-CoV-2 3CL protease (3CL Pro), with an IC50 value of 369.5 nM. This compound demonstrates potent antiviral activity against SARS-CoV-2 and is valuable for research applications focused on developing therapeutic strategies for COVID-19. Its mechanism of action provides insights into viral replication processes, making it an essential tool for virology studies and drug discovery efforts targeting SARS-CoV-2. -
SARS-CoV-2 Mpro Inhibitor
M56-S2 iodide is a selective inhibitor of the SARS-CoV-2 main protease (Mpro) with an IC50 value of 4.0 μM. This compound demonstrates favorable oral bioavailability and exhibits low toxicity based on ADMET predictions, indicating its potential as a therapeutic agent. M56-S2 iodide serves as a valuable tool in antiviral research, particularly in the study of SARS-CoV-2 and related coronaviruses. -
SARS-CoV-2 Inhibitor
ZINC61142882 is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase, exhibiting an IC50 value of 6 μM. This compound demonstrates antiviral activity by disrupting viral RNA cap methylation, which is essential for RNA stability and immune evasion. It is suitable for research focused on COVID-19 therapeutic development and the exploration of viral RNA modifications. -
SARS-CoV-2 Inhibitor
TO-195 hydrochloride is a protease inhibitor that specifically targets severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It exhibits antiviral activity and shows potential as a therapeutic agent for the study of coronavirus disease 2019 (COVID-19). This compound is valuable for researchers investigating SARS-CoV-2 protease mechanisms and developing novel antiviral strategies. -
SARS-CoV-2 Inhibitor
Antiviral agent 25 is a novel non-peptide analog that functions as a covalent inhibitor of SARS-CoV-2 3CLpro and PLpro. It demonstrates potent inhibitory activity against these proteases, with IC50 values of 0.118 µM and 0.448 µM, respectively. Additionally, antiviral agent 25 exhibits effective antiviral activity against SARS-CoV-2, showing an EC50 value of 7.249 µM. This compound is valuable for research on viral replication and inhibition in SARS-CoV-2 studies. -
SARS-CoV Inhibitor
XR8-69 is a potent inhibitor of the SARS-CoV-2 main protease (PLpro), demonstrating low micromolar antiviral activity in infected human cells. This compound is valuable for research focused on antiviral strategies against SARS-CoV-2, offering insights into the inhibition of viral replication and potential therapeutic avenues in COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-40 is a potent inhibitor of the SARS-CoV-2 virus, specifically targeting BA.1 and BA.5 variants. This compound demonstrates biological activity through its ability to inhibit viral infection in Calu3 lung cells, achieving IC50 values of 100 nM and 160 nM for the respective variants. SARS-CoV-2-IN-40 serves as a valuable tool for research focused on understanding and combating SARS-CoV-2 infections. -
SARS-Cov-2-Mpro inhibitor
GRL-190-21 is a potent inhibitor of SARS-CoV-2 main protease (Mpro), exhibiting a dissociation constant (Ki) of 0.04 nM. This compound demonstrates significant antiviral activity, with an effective concentration (EC50) of 0.26 μM in Vero E6 cells. GRL-190-21 effectively reduces the infectivity, replication, and cytopathic effects of SARS-CoV-2, while maintaining a favorable safety profile with minimal toxicity. This compound is valuable for research focused on antiviral drug development and elucidating coronavirus pathogenesis. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-45 is a potent inhibitor of the main protease (Mpro) of SARS-CoV-2, with IC50 values of 0.12 μM for HCoV-OC43 Mpro and 0.16 μM specifically for SARS-CoV-2 Mpro. This compound demonstrates effective antiviral activity, making it valuable for research into therapeutic strategies against COVID-19 and related coronaviruses. Its oral bioavailability further enhances its potential applications in drug development and infectious disease studies. -
SARS-CoV-2 3CLpro Inhibitor
Hydroxyethylamine is a selective inhibitor of the SARS-CoV-2 3CLpro enzyme, exhibiting an IC50 of approximately 10 μM in viral spread assays. This compound demonstrates potent antiviral activity, making it a valuable tool for research targeting SARS-CoV-2 replication and infection mechanisms. Its application is critical in the development of therapeutic strategies against COVID-19.
